AMAG PHARMACEUTICALS, INC. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization
Impairment of long-lived assets
Provision for bad debt expense
Amortization of premium/discount on purchased securities
Write-down of inventory
(Gain) loss on disposal of fixed assets
Non-cash equity-based compensation expense
Non-cash IPR&D expense
Non-cash loss on debt extinguishment
Loss on debt extinguishment
CBR Acquisition Holdings Corp
Total loss on debt extinguishment

Amortization of debt discount and debt issuance costs
(Gain) loss on sale of marketable securities, net
Change in fair value of contingent consideration
Lumara Health
MuGard
Total change in fair value of contingent consideration

Deferred income taxes
Non-cash lease expense
Gain on sale of the CBR business
Transaction costs
Changes in operating assets and liabilities:
Accounts receivable, net
Inventories
Receivable from collaboration
Prepaid and other current assets
Other long-term assets
Accounts payable and accrued expenses
Deferred revenues
Other long-term liabilities
Repayment of term loan attributable to original issue discount

Net cash provided by (used in) operating activities

Acquisition of Lumara Health, net of acquired cash
Deferred revenues
Payment of contingent consideration in excess of acquisition date fair value
Repayment of term loan attributable to original issue discount
Other assets and liabilities
Net cash (used in) provided by operating activities

Cash flows from investing activities:
Acquisition of Lumara Health, net of acquired cash
CBR Acquisition Holdings Corp
Total acquisition of Lumara Health, net of acquired cash

Acquisition of CBR, net
Proceeds from sales or maturities of marketable securities
Purchases of marketable securities
Acquisition of intangible asset
Vyleesi Products
Intrarosa
Total acquisition of intangible asset
Change in restricted cash
Capital expenditures, net of proceeds from sale of assets
Net cash (used in) investing activities
Proceeds from the sale of the CBR business
Note receivable
Capital expenditures
Net cash provided by investing activities

Cash flows from financing activities:
Proceeds from the issuance of common stock, net of underwriting discount and other expenses
Proceeds from long-term debt
Long-term debt principal payments
Proceeds from 2022 Convertible Notes
Proceeds from 2015 term loan
Payments to repurchase 2019 Convertible Notes
Payment of premium on debt extinguishment
Proceeds to settle warrants
Payment of convertible debt issuance costs
Proceeds from issuance of warrants
Purchase of convertible bond hedges
Payment of contingent consideration
Payment to former CBR shareholders
Payments for repurchases of common stock
Proceeds from the issuance of common stock under the ESPP
Proceeds from the exercise of common stock options
Proceeds from the issuance of common stock under ESPP
Net cash provided by financing activities
Net increase (decrease) in cash and cash equivalents
Payments of employee tax withholding related to equity-based compensation
Net cash used in financing activities

Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents at beginning of the year
Cash and cash equivalents at end of the year
Net (decrease) increase in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of the year
Cash, cash equivalents and restricted cash at end of the year
Supplemental data of cash flow information:
Cash (refunded) paid for taxes
Cash paid for interest
Non-cash investing and financing activities:
Fair value of acquisition-related contingent consideration
Right-of-use assets obtained in exchange for lease obligations
Settlement of note receivable in connection with Perosphere acquisition
Contingent consideration accrued for the acquisition of the Intrarosa intangible asset

Comments